About this item:

686 Views | 0 Downloads

Author Notes:

Correspondence: Taofeek K. Owonikoko, M.D., Ph.D., Department of Hematology and Medical Oncology, Emory University School of Medicine, 1365C Clifton Road, NE Room C3080, Atlanta, GA 30322, USA. Telephone: 404-778-5575; Fax: 404-778-5520; e-mail: towonik@emory.edu

Disclosures of potential conflicts of interest may be found at the end of this article.

Subject:

Research Funding:

The author was supported by the National Cancer Institute (1K23CA164015), Georgia Cancer Coalition and the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000454.

Keywords:

  • Phase I
  • Autonomy
  • Informed consent
  • Protocol deviation

Upholding the Principles of Autonomy, Beneficence, and Justice in Phase I Clinical Trials

Tools:

Journal Title:

Oncologist

Volume:

Volume 18, Number 3

Publisher:

, Pages 242-244

Type of Work:

Article | Post-print: After Peer Review

Abstract:

This commentary discusses the importance of maintaining the three core principles of autonomy, beneficence, and justice in phase I clinical trials.

Copyright information:

©AlphaMed Press

Export to EndNote